Regeners
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Regeners - overview
Established
2021
Location
Daejeon, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2021, and based in Daejeon, South Korea, Regeners Inc. is a biotechnology company that conducts research and development of stem cell therapeutics using its proprietary direct reprogramming technology to develop cell regeneration medicine. In October 2022, Regeners raised seed funding from new investor TheVentures. As of January 2023, the company is being led by its CEO, Ha Kang Kim, and its partners include Bluepoint and Y’sLetter.
The firm employs its proprietary PDR technology (Pluripotency factor-mediated Direct Reprogramming) that analyzes cells in the intermediate stages and induces direct cross-differentiation/development to create a variety of therapeutic cells. The generated cells can be used to reverse the aging in cells and also generate additional nerve cells, cardiomyocytes, liver cells, etc.
Current Investors
Bluepoint Partners, GTO Investment, The Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.regenersinc.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.